CD44基因多态性与乳腺癌对蒽环类药物化疗敏感性的关系

Association of CD44 polymorphisms with chemosensitivity to anthracycline-based chemotherapy in breast cancer

目的:研究CD44基因rs4756195位点不同基因型乳腺癌患者对蒽环类药物化疗敏感性的差异,阐明CD44基因多态性与乳腺癌对蒽环类药物化疗敏感性的关系。方法:利用Sequenom MassArrayRiPLEX GOLD系统检测120例接受以蒽环类药物为基础的新辅助化疗的乳腺癌患者CD44基因rs4756195位点多态性,2～3个治疗周期后,以非条件Logistic回归模型比较携带不同基因型的乳腺癌患者之间化疗总有效率和病理完全缓解率的差异。结果:携带GG基因型与携带AA和AG基因型的乳腺癌患者术前新辅助化疗总有效率差异无统计学意义(73.6%vs 69.0%,χ2=0.240,P=0.625);携带AA和AG基因型的乳腺癌患者的病理完全缓解率明显高于携带GG基因型的乳腺癌患者(55.2%vs 16.5%,χ2=17.181,P=0.000;OR=13.935,95%CI=4.359～44.541,P=0.000)。结论:CD44基因rs4756195位点多态性与乳腺癌对蒽环类药物的化疗敏感性有关联,携带AA和AG基因型的乳腺癌患者有较高的病理完全缓解率,提示CD44基因rs4756195位点多态性可能成为预测乳腺癌化疗疗效的指标之一。

Objective To study the chemosensitivity difference of diffferent genotypes of CD44 at rs4756195 to anthracyclines-based chemotherapy in breast cancer patients and clarify the association between CD44 polymorphisms and their chemosensitivities to anthracyclines-based chemotherapy in breast cancer.Methods The polymorphisms of CD44 at rs4756195 in a total of 120 patients with breast cancer treated with anthracycline-based neoadjuvant chemotherapy were detected by Sequenom MassArray○ R iPLEX GOLD System.After 2 to 3 cycles of chemotherapy,the differences in the overall response and the rate of pathological complete remission（pCR） were analyzed with Logistic regression analysis.Results The overall response of the patients with breast cancer who carried with GG genotype had no significant difference compared with those carried with AA and AG genotypes（73.6% vs 69.0%,χ2=0.240,P=0.625）,and the rate of pCR in breast cancer patients carried with AA and AG genotypes was higher than those carried with GG genotype（55.2% vs 16.5%,χ2=17.181,P=0.000;OR=13.935,95%CI=4.359-44.541,P=0.000）.Conclusion CD44 rs4756195 polymorphisms are closely associated with the response to anthracyclines-based chemotherapy in breast cancer patients,and the patients with breast cancer who carried with A allelotype have the higher rate of pCR.CD44 rs4756195 polymorphisms may be used as one of the indicators to evaluate the chemotherapeutic response of the patients with breast cancer.